Abstract
KRAS is mutated in 25% of non-small cell lung cancer (NSCLC) adenocarcinoma, with KRAS G12C and G12V mutations occurring in ∼13% and ∼7% of patients, respectively. Whereas G12C inhibitors (G12Ci) sotorasib (AMG 510) and adagrasib (MRTX849) have demonstrated promising antitumor activity in patients with KRAS G12C mutant (mt) NSCLC, KRAS G12V mt NSCLC remains an unmet need. VS-6766 is a unique dual RAF/MEK inhibitor which has shown single agent activity against KRAS G12V mt NSCLC (Guo Lancet Oncology 2020).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
